Maze Therapeutics, Inc. share price logo

Maze Therapeutics, Inc.

NASDAQ: MAZE

Small Cap

$34.33

-1.76

(-4.88%)

as on

Maze Therapeutics, Inc. Stock Performance

as on November 14, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $32.53
    $35.30
    downward going graph

    5.24%

    Downside

    2.83%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $21.95
    $53.65
    downward going graph

    36.06%

    Downside

    56.28%

    Upside

    downward going graph

Maze Therapeutics, Inc. share price movements today

Previous Close
$36.09
Open
$35.22
Volume
1.2M
Market Cap
$2.0B
Day's Low - High
$32.53 - $35.30
52 Week Low - High
$21.95 - $53.65

Maze Therapeutics, Inc. Historical Returns

1 Month Return
+ 30.88 %
3 Month Return
+ 26.31 %
1 Year Return
+ 5.53 %
3 Year Return
0 %
5 Year Return
0 %

Maze Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Maze Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.0B

EPS (TTM)

-2.87

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-12.62

Industry PE ratio

-6.17

PEG Ratio

0.42

EBITDA

-147.0M

Revenue (TTM)

20.0M

Profit Margin

95.28%

Return On Equity TTM

-38.39%

Maze Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Maze Therapeutics, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Maze Therapeutics, Inc. image
Maze Therapeutics, Inc.
StrongBuy$2.0BNA-12.6295.28%0.00%
Moderna image
Moderna
Neutral$100.6B0.07%-35.1828.00%0.00%
BeOne Medicines image
BeOne Medicines
StrongBuy$47.5BNA68.7388.39%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$137.6B187.58%34.7885.57%0.00%
Regeneron image
Regeneron
Buy$99.2B51.37%20.2985.77%0.39%

Stock Returns calculator for Maze Therapeutics, Inc. Stock including INR - Dollar returns

The Maze Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

Maze Therapeutics, Inc. investment value today

Current value as on today

₹1,12,206

Returns

₹12,206

(+12.21%)

Returns from Maze Therapeutics, Inc. Stock

₹5,533 (+5.53%)

Dollar Impact

₹6,672 (+6.67%)

Analyst Recommendation on Maze Therapeutics, Inc. Stock

Based on 8 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 8 analysts, 100% of analysts recommend a 'BUY' rating for Maze Therapeutics, Inc.. Average target price of $62.625

Maze Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Maze Therapeutics, Inc..

Current Price

$34.33

Analyzed by

8 Analysts

High

$110

0

Low

$46

Maze Therapeutics, Inc. target price $0, a slight upside of 0% compared to current price of $34.33. According to 8 analysts rating.

Indian Investors' Interest in Maze Therapeutics, Inc. Stock

Search interest for Maze Therapeutics, Inc. Stock has decreased by -70% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-70% versus previous 30 day period

Maze Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Jun 2024
Sep 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
-
165
2
-
-
-
-
20
-
-
Gross Profit
-
165
2
-
0
-
0
19
-
-
Operating Income
-23
139
-24
-35
-36
-32
-38
-26
-48
-51
EBITDA
-25
141
-24
-32
-33
-29
-34
-22
-43
-46
Interest Expense
-
-
-
-
-
-
-
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-26
140
-25
-32
-33
-30
-34
-24
-44
-47
Income Tax Expense
-
1
0
-
-
-
-
-
-
-
Net Income
-26
139
-24
-32
-33
-30
-34
-24
-44
-47
Net Profit Margin
0.00%
100.00%
100.00%
0.00%
0.00%
0.00%
0.00%
97.78%
0.00%
0.00%

Maze Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2022
Dec 2023
Mar 2025
Dec 2025
Total Revenue
-
-
167
-
Gross Profit
-
-
167
-2
Operating Income
-111
-98
57
-142
EBITDA
-111
-96
56
-128
Interest Expense
-
-
-
-
Depreciation
3
4
3
2
Income Before Tax
-114
-100
53
-131
Income Tax Expense
-
-
1
-
Net Income
-114
-100
52
-131
Net Profit Margin
0.00%
0.00%
100.00%
0.00%

Maze Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Jun 2024
Sep 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
-26
139
-24
-32
-33
-30
-34
-24
-44
-47
Operating Cash Flow
-20
145
-23
-29
-30
-24
-27
-39
-15
-32
Investing Cash Flow
0
0
0
0
0
-66
-103
6
-128
-31
Financing Cash Flow
16
0
-2
127
0
143
3
42
147
15
Change in Cash
-4
145
-25
97
-29
52
-127
9
3
-48

Maze Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2022
Dec 2023
Mar 2025
Dec 2025
Net Income
-114
-100
52
-131
Operating Cash Flow
-99
-86
75
-111
Investing Cash Flow
-3
0
-1
-170
Financing Cash Flow
1
16
92
275
Change in Cash
-100
-70
167
-7

Global Institutional Holdings in Maze Therapeutics, Inc.

Check out the Institutions with significant holdings in Maze Therapeutics, Inc..

Funds
Holdings
BlackRock, Inc.
6.41%
Vanguard
3.93%
iShares
3.53%
VANGUARD INDEX FUNDS
3.18%
Andrew J.M. Spokes
2.03%
See all

Maze Therapeutics, Inc. News & Key Events

  • img

    Today's Timeline - 10 November

    Tue, 11:11 PM

    -

    Maze Therapeutics reports Q3 EPS of 79c, exceeding consensus of 75c, with a net loss of $48M.

Insights on Maze Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, MAZE stock has moved up by 24.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 801.8% return, outperforming this stock by 796.3%

About Maze Therapeutics, Inc.

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
OrganisationMaze Therapeutics, Inc.
Headquarters171 Oyster Point Blvd, South San Francisco, CA, 94080, US
IndustryBiotechnology
CEOJason Coloma

Key Management of Maze Therapeutics, Inc.

Name

Title

Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D.

CEO & Director

Mr. Vipin Vijayakumar

Senior Vice President of Technology and Business Operations

Mr. Atul Dandekar

Chief Strategy & Business Officer

Mr. Winston Tse

Senior Vice President of Drug Discovery

Mr. Misbah Tahir CPA

CFO & Principal Accounting Officer

Dr. Harold S. Bernstein M.D., Ph.D.

President of Research & Development and Chief Medical Officer

Mr. Maarten Hoek

Chief Scientific Officer

Ms. Courtney J. Phillips J.D.

General Counsel & Corporate Secretary

Mr. Matt Krause

Senior Vice President of Human Resources

Ms. Nazila Habibizad

Senior Vice President of Technical Operations & Supply Chain

FAQs

What is Maze Therapeutics, Inc. share price today?

Maze Therapeutics, Inc. share price today is $34.33 as on at the close of the market. Maze Therapeutics, Inc. share today touched a day high of $35.30 and a low of $32.53.

What is the 52 week high and 52 week low for Maze Therapeutics, Inc. share?

Maze Therapeutics, Inc. share touched a 52 week high of $53.65 on and a 52 week low of $21.95 on . Maze Therapeutics, Inc. stock price today i.e. is closed at $34.33,which is 36.01% down from its 52 week high and 56.40% up from its 52 week low.

What is Maze Therapeutics, Inc.'s market capitalisation today?

Maze Therapeutics, Inc. market capitalisation is $0.00T as on .

How to invest in Maze Therapeutics, Inc. Stock (MAZE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Maze Therapeutics, Inc. on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Maze Therapeutics, Inc. Stock (MAZE) from India?

Indian investors can start investing in Maze Therapeutics, Inc. (MAZE) shares with as little as ₹94.23999786376953 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹942.40 in Maze Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Maze Therapeutics, Inc. share’s latest price of $34.33 as on November 14, 2026 at 8:45 am IST, you will get 0.2913 shares of Maze Therapeutics, Inc.. Learn more about fractional shares .